Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,493 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Results available

Stress Neuroadaptation in Tobacco Dependence

NCT03262233
Conditions
Nicotine Dependence
Interventions
nicotine, placebo
Combination Product · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Melanoma
Interventions
DNX-2401
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

NCT00001832
Conditions
Melanoma, Neoplasm Metastasis
Interventions
gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

Lutronic LaseMD for Treatment of Benign Pigmented Lesions

NCT03409952
Conditions
Benign Pigmented Lesions
Interventions
LaseMD and DUAL 1927nm Laser, LaseMD
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Hunt Valley, Maryland • Charlotte, North Carolina
Completed Not applicable Interventional

ASD Wearables Feasibility Study

NCT07504224
Conditions
Autism Spectrum Disorder, Wearable Devices
Interventions
14-Day Device Monitoring
Device
Lead sponsor
Rady Pediatric Genomics & Systems Medicine Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Diego, California
Conditions
Recurrent Head and Neck Cancer
Interventions
PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2, PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
Combination Product
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 4 more
Completed Phase 2 Interventional Results available

The Fibrin Patch Soft Tissue Study

NCT00658723
Conditions
Hemostasis
Interventions
Fibrin Pad, SURGICEL™
Drug · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 6 more
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

NCT04329923
Conditions
COVID-19
Interventions
Hydroxychloroquine Sulfate 400 mg twice a day, Hydroxychloroquine Sulfate 600 mg twice a day, Hydroxychloroquine Sulfate 600 mg once a day, Placebo oral tablet
Drug
Lead sponsor
Ravi Amaravadi, MD
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 2 Interventional Results available

Aging Mammary Stem Cells and Breast Cancer Prevention

NCT02642094
Conditions
Cancer of Breast
Interventions
Rapamycin
Drug
Lead sponsor
LuZhe Sun
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Moderate to Severe Chronic Plaque-Type Psoriasis
Interventions
AIN457 150 mg, AIN457 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Fresno, California • Pasadena, California • San Francisco, California + 24 more
Conditions
Healthy
Interventions
Duragesic (Fentanyl Transdermal System [TDS] Small Patches), New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches), Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches), Duragesic (Fentanyl TDS Large Patches), New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches), Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Conditions
Atrial Fibrillation, Mitral Valve Insufficiency, Mitral Valve Stenosis
Interventions
MVS, Ablation
Procedure · Device
Lead sponsor
Annetine Gelijns
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
18
States / cities
New Haven, Connecticut • Newark, Delaware • Atlanta, Georgia + 14 more
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
cetuximab
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
San Francisco, California • Chicago, Illinois • Lexington, Kentucky + 5 more
Terminated Phase 2 Interventional Results available

Spesolimab in Pyoderma Gangrenosum

NCT06092216
Conditions
Pyoderma Gangrenosum
Interventions
Spesolimab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia

NCT07788755
Conditions
Schizophrenia, Schizoaffective Disorder, Cognitive Impairment, Visual Impairment
Interventions
Perceptual Discrimination Training, Cognitive Control Training
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 79 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Estradiol Addback

NCT01862835
Conditions
Normal Healthy Volunteers
Interventions
Degarelix, Testosterone, Anastrozole, Estrogen patch
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years to 80 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Hypertension, Resistant to Conventional Therapy, Atrial Fibrillation
Interventions
Circumferential PV isolation, Circumferential PVI+renal denervation
Procedure
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Actinic Keratosis
Interventions
AM001 Cream, 7.5%, Vehicle Cream
Drug
Lead sponsor
AmDerma
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
High Point, North Carolina
Conditions
Prostate Adenocarcinoma, Prostate Cancer
Interventions
Transvesical Single Port Robotic Partial Prostatectomy, High-intensity focused ultrasound (HIFU)
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Lateral Ankle Instability
Interventions
MBP plus arthroscopy (Group A), MBP alone (Group B)
Procedure
Lead sponsor
Edna Rath
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
El Paso, Texas
Withdrawn Not applicable Interventional

NEUWAVE Flexible Probe Study #2

NCT03713099
Conditions
Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Interventions
Microwave ablation
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Duarte, California • Rochester, Minnesota • New York, New York + 2 more
Conditions
Smoking Cessation, Smoking, Nicotine Dependence
Interventions
Varenicline, Nicotine lozenge, Nicotine Patch
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
1,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis

NCT07515872
Conditions
Arthritis, Osteo Arthritis of the Knee
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, Intra articular injection
Device · Drug
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
65 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Stamford, Connecticut • Dryden, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validation Study: Extended Wear Performance of the Zio Monitor - SHASTA II

NCT07205367
Conditions
Cardiac Arrhythmia
Interventions
Zio Monitor
Device
Lead sponsor
iRhythm Technologies, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
San Francisco, California • Deerfield, Illinois